RedHill Biopharma (RDHL) Tops Q4 EPS Views

RedHill Biopharma (NASDAQ: RDHL) reported Q4 EPS of $0.06, $0.66 better than the analyst estimate of ($0.60).

EPS in Q413 was 0.05.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Isabella Bank added to Russell 2000 index after Nasdaq listing
• Aecon wins $1.7B share of Alberta power plant contract